Applications of Bionano Sensor for Extracellular Vesicles Analysis

Jin-Ha Choi 1, Jin-Ho Lee 2,● and Jeong-Woo Choi 1,*

1 Department of Chemical and Biomolecular Engineering, Sogang University, Seoul 04107, Korea; jinhachoi@sogang.ac.kr  
2 School of Biomedical Convergence Engineering, Pusan National University, Yangsan 50612, Korea  
* Correspondence: leejh@pnu.ac.kr (J.-H.L.); jwchoi@sogang.ac.kr (J.-W.C.); Tel.: (+82) 51-510-8547 (J.-H.L.); (+82) 2-705-8480 (J.-W.C.); Fax: (+82) 2-3273-0331 (J.-W.C.)

Received: 15 July 2020; Accepted: 17 August 2020; Published: 21 August 2020

Abstract: Recently, extracellular vesicles (EVs) and their contents have been revealed to play crucial roles in the intrinsic intercellular communications and have received extensive attention as next-generation biomarkers for diagnosis of diseases such as cancers. However, due to the structural nature of the EVs, the precise isolation and characterization are extremely challenging. To this end, tremendous efforts have been made to develop bionano sensors for the precise and sensitive characterization of EVs from a complex biologic fluid. In this review, we will provide a detailed discussion of recently developed bionano sensors in which EVs analysis applications were achieved, typically in optical and electrochemical methods. We believe that the topics discussed in this review will be useful to provide a concise guideline in the development of bionano sensors for EVs monitoring in the future. The development of a novel strategy to monitor various bio/chemical materials from EVs will provide promising information to understand cellular activities in a more precise manner and accelerates research on both cancer and cell-based therapy.

Keywords: biosensors; extracellular vesicle; nanoparticle; nanotechnology; optical sensor; electrochemical sensor

1. Introduction

Recently, extracellular vesicles (EVs) (50–200 nm in diameter) have emerged as a new biomarker to diagnose disease progression and monitor treatment efficacy because of their vital role in cell–cell communication and molecular exchange [1–3]. These cell-derived membrane-enclosed vesicles are physically stable, abundant in biological fluids (e.g., >10^10 EVs/mL of blood) and carry cell-specific cargos that are characteristic of their cells of origin, including proteins and nucleic acids (e.g., micro RNA (miRNA), messenger RNA (mRNA) and DNA) [4–7]. Typically, extracellular vesicles are enriched with a transport or fusion protein (e.g., caveolin-1), tetraspanins (e.g., CD63, CD9, CD81) and heat-shock proteins (Hsp 60, Hsp 70 and Hsp 90) due to the endosomal formation of vesicles [8]. Most of the nucleic acids (approximately 76% of the total oligonucleotides) inside EVs are non-coding RNAs (i.e., miRNAs), which are involved in many different roles and functions of cells as post-transcriptional gene regulators [9,10]. Furthermore, because EVs are actively secreted in large quantities by cells, they are promising biomarker candidates for the early diagnosis of diseases and sub-sequential monitoring of the therapeutic response from liquid biopsies in a minimally invasive manner [11].

Despite such clinical potential, the reliable isolation and analyses of EVs from complex biologic fluids are enormously challenging because of the small size and low density of these biomolecules, thereby necessitating an extensive sample preparation technique before measurements. Although ultracentrifugation remains the gold standard for isolation of extracellular vesicles, it still
requires expensive instruments, tedious steps and may introduce some impurities [5,12]. Meanwhile, conventional analytical methods, including western blotting, enzyme-linked immunosorbent assay (ELISA) and flow cytometry, have also been facing technical hurdles owing to the limited sample volume, low sensitivity, and/or requirement of specialized high-end equipment [13–17]. For example, the quantification of EVs by ELISA has a limit of approximately 10⁴ in 100-µL of the sample [18]. To improve the efficiency and sensitivity of EV isolation from a complex biologic fluid, various nanotechnology-based biosensors have been developed [19–21].

This review describes some of the current state-of-the-art developments in nanotechnology-based biosensor platforms for analyzing exosomal proteins and RNAs. These approaches are classified into four broad categories: surface plasmon resonance (SPR), colorimetric/fluorescence, Raman and electrochemical. The topics discussed in this review provide some insight into and guidelines for developing a nanotechnology-based EV characterization platform to promote the translation of EVs into clinical applications.

2. Surface Plasmon Resonance-Based Analysis Methods for EV Detection

The SPR-based analytical method is an efficient platform for detecting and characterizing molecular interactions between biologic molecules [22–26]. This method monitors local refractive index changes generated by the resonant oscillation of stimulated electrons near the sensing surface (i.e., nanoscale metal materials) upon the binding of a ligand to a target molecule [27–31]. Owing to this simple and distinctive phenomenon, SPR-based biosensors have gained extensive attention to develop label-free and real-time biosensors with minimal sample preparation procedures [32–36]. Furthermore, as the dimension of EVs perfectly matches the sensing depth of SPR (200 nm), SPR-based biosensors are effective for quantifying EVs from complex biologic fluids [37–40]. In this section, recent studies related to SPR-based exosomal detection platforms are briefly introduced.

Qiu et al. utilized a nano-thick titanium nitride (TiN) film as an alternative plasmonic material in the SPR biosensing system for sensitive detection of EVs derived from malignant glioma cells (U251) (Figure 1A) [41]. Based on the high affinity between the TiN film surface and biotin, the TiN film was functionalized by biotinylated anti-epidermal growth factor receptor (EGFR) variant-III (EGFR vIII) antibodies or anti-CD63 to capture U251-derived EVs. Both an in vitro cell culture condition and serum were tested to validate the performance of the biosensor in a real sample condition (i.e., complex biologic fluid). The developed biosensor had a limit of detection (LOD) of 4.29 × 10⁻³ µg/mL for a general EV marker (CD63) and 2.75 × 10⁻³ µg/mL for the glioma cell-specific marker, EGFR vIII. Compared with well-known plasmonic metal materials, including gold (Au), TiN even demonstrated better sensitivity, while having a tunable plasmonic property in the visible to near-infrared spectrum range as well.

In addition to detecting classic antigen–antibody interactions, the SPR-based approaches have proved useful for the sensitive and selective determination of EVs based on aptamer recognition. For example, Wang et al. demonstrated how a sensitive aptasensor could be used for EV detection by SPR with controlled two-step hybridization of Au nanoparticle (NP)-assisted signal amplification (Figure 1B) [42]. Briefly, aptamer CD63 that targets the general EV surface marker CD63 was functionalized on surfaces of Au film to capture EVs. The addition of Au NPs modified with two different aptamers (CD63 and T30, where T30 is 5′-TTT (×10)-3′) led the first signal amplification by forming a sandwich structure “CD63-aptamer-modified Au film/EV/CD63 aptamer and T30-aptamer-modified Au NPs”. A second signal amplification was obtained by employing aptamer A30 (5′-AAA (×10)-3′)-functionalized Au NPs to capture the T30 sequence by the complementary base pairing procedure based on the A–T interaction. The consequent electronic coupling between (1) the Au film and Au NPs and (2) the Au NPs and Au NPs changed the local refractive index, separately, enabling dual-signal amplification. By utilizing this dual Au NP-assisted signal amplification, the authors achieved high sensitivity and low LOD (5 × 10⁴ EVs/mL), corresponding to a 10⁴-fold improvement compared with ELISA. Moreover, the developed SPR-based sensor system could detect the EVs in
complex biologic fluids (30% fetal bovine serum) and differentiate the EVs secreted by two different cell lines (MCF-10A normal breast cells and MCF-7 breast cancer cells).

Figure 1. Surface plasmon resonance (SPR) biosensor for extracellular vesicles (EV) detection. (A) Schematic illustration of TiN nano-thick film functionalized by the anti-CD63 antibody for the detection of EVs; (B) dual Au Np-assisted signal amplification for the determination of EVs; (C) biophysical interaction of EV with self-assembled Au NIs without functionalization; (D) Au nanoplasmonic array functionalized with the anti-CD63 antibody for LSPR based digitalized detection of the EV. (reproduced with permission from [41] published by Wiley-VCH 2019, reproduced with permission from [42] published by Elsevier 2019, reproduced with permission from [43] published by Elsevier 2017 and reproduced with permission from [44] published by Public Library of Science 2018).

Alternatively, Im et al. reported an on-chip nanoplasmonic EV sensor (nPLEX) for high-throughput EV protein analysis based on the localized surface plasmon resonance (LSPR) mechanism [45]. The chip comprises an Au layer with periodic nanohole arrays functionalized with different antibodies for binding specific EVs and profiling of EV surface proteins and proteins present in EV lysates (71 protein biomarkers in ovarian cancer and benign cells were analyzed). In detail, the Au nanoholes were designed with a probing depth of less than 200-nm to match the size of the EV (<100 nm) to improve sensitivity. With target-specific binding of EV, the spectral intensity or shifts changes proportional to the target marker protein levels were successfully obtained, and the LOD of the nPLEX chip was estimated to be 3000 EVs/mL (670 aM). In addition, when samples from cancer patients were analyzed, ovarian cancer correlated with the expression of CD24 and epithelial cell adhesion molecule (EpCAM).

Thakur et al. used a self-assembled array of Au nanoislands to develop a sensitive and low-cost LSPR-based biosensors for detecting EVs isolated from A-549 cells, SH-SY5Y cells, blood serum and urine from a lung cancer mouse model (Figure 1C) [3]. The active structure of the Au nanoislands array was constructed by deposition and annealing procedures and utilized for the detection of EVs without any surface functionalization. The LOD of this sensor was 0.194 µg/mL. Similarly, Bathini et al. demonstrated an Au nanoislands-assisted EV detection system functionalized with a peptide called
Venceremin (Vn96) [46]. Vn96 is a synthetic peptide with a strong affinity for heat-shock proteins on the surface of EVs. With a simple physical model, the optimum streptavidin–biotin–polyethylene glycol–Vn96 complex formation condition was achieved and experimentally optimized in agreement with the physical model. It was found that the surface of each Au nanoislands could accommodate nine EVs, resulting in 27 EVs/µm².

In another example, Raghu et al. fabricated Au nanoplasmonic pillar arrays by combining nano- and microfabrication techniques for single EV detection (Figure 1D) [44]. By limiting the size of the individual elliptically shaped nanoplasmonic pillar similar to the size of an EV (approximately 100 nm), in situ EV binding events (secreted by MCF7 breast adenocarcinoma cells) were observed, even at sub-femtomolar concentrations. Recent studies of SPR-and LSPR-based analytical methods for detecting EVs are compared in Table 1.

| Method                  | Working Principle                                                                 | Target                      | Correlation Range          | Detection Limit        | Ref  |
|-------------------------|-----------------------------------------------------------------------------------|-----------------------------|----------------------------|------------------------|------|
| SPR                     | TiN film functionalized by biotinylated anti-epidermal growth factor receptor variant-III (EGFRvIII) antibodies | Glioma cells (U251)         | 0.005–500 µg/mL            | 2.75 × 10⁻³ µg/mL      | [41] |
|                         | Dual signal amplification via two-step hybridization using aptamer functionalized Au NPs | MCF-7 breast cancer cells and MCF-10A normal breast cells | Not stated                  | 50 EVs/µL              | [42] |
| LSPR                    | Periodic nanohole arrays with gold layer functionalized antibodies                | Ovarian cancer              | 4.03 × 10²–1.32 × 10⁶ EVs µL | 4.03 × 10⁵ EVs/µL     | [43] |
|                         | Self-assembled Au NIs without functionalization                                   | A-549 and SH-SY5Y cells    | 0.194–100 µg/mL            | 0.194 µg/mL            | [43] |
|                         | Au nanoplasmonic array functionalized with anti-CD63 antibody                    | Breast cancer               | Not stated                  | 1 × 10⁶ EVs/µL         | [46] |

3. Colorimetric/Fluorescence-Based Analysis Methods for EV Detection

During the past few years, various types of nanomaterials with unique optical properties have been extensively applied to develop sensitive biosensors for EV analysis [21, 47]. Among the optical techniques, a promising nanotechnology-based colorimetric biosensor has been established to detect exosomal biomarkers with the naked eye based on the extinction coefficient [48–50]. In general, nanotechnology-based colorimetric biosensors can be characterized into two groups based on their different properties of nanomaterials: catalytic properties (i.e., nanozymes) and inherent optical properties [51]. As an example of the catalytic property, Chen et al. improved the sensitivity of the traditional ELISA by fabricating a three-dimensional (3D) zinc oxide (ZnO) nanowires-coated scaffold chip device (Figure 2A) [52]. The presence of a hierarchical nanointerface, which was obtained by a 3D polydimethylsiloxane scaffold and free-standing ZnO nanowires, provides high capture efficiency of EVs as a result of the large surface area, as well as a size exclusion-like effect. After the isolation, a colorimetric assay based on horseradish peroxidase (HRP)-labeled antibody and 3,3′,5,5′-tetramethylbenzidine was performed for the quantitative analysis of EVs. Based on the improved sensitivity compared with a commercial ELISA, down to 2.2 × 10⁴ EVs/µL was detected with a linear range of 2.2 × 10⁵–2.4 × 10⁷ EVs/µL. Likewise, Zhang et al. integrated a microfluidic chip with self-assembled 3D herringbone nanopatterns to promote microscale mass transfer by increasing the surface area for efficient EV isolation [53]. Combined with a colorimetric method, the LOD achieved was down to 10 EVs/mL. Moreover, the quantitative detection of circulating exosomal CD24, EpCAM and folate receptor–alpha protein for diagnosing ovarian cancer was demonstrated using only 2 µL of plasma.
Figure 2. Colorimetric/fluorescence biosensor for EV detection. (A) Schematic diagram of the ZnO-nanowires-coated three-dimensional (3D) scaffold chip for EV detection; (B) utilization of peroxidase-like activity of graphitic carbon nitride nanosheets (g-C$_3$N$_4$ NSs); (C) fluorescence resonance energy transfer (FRET) biosensing system based on aptamer and graphene oxide (GO); (D) multifunctional nanorods (NRs) based exosomal miRNA signal amplification based on metal-enhanced fluorescence effect. (reproduced with permission from [52] published by Elsevier 2018, reproduced with permission from [54] published by American Chemical Society 2017, reproduced with permission from [55] published by American Chemical Society 2018 and reproduced with permission from [63] published by American Chemical Society 2019).

As an alternative approach to improve sensitivity for EV detection, Wang et al. utilized the inherent peroxidase-like activity of graphitic carbon nitride (g-C$_3$N$_4$) nanosheets for a colorimetric assay (Figure 2B) [54]. In addition to the peroxidase-like activity of g-C$_3$N$_4$ nanosheets, the adsorption of single-stranded DNA (ssDNA) was also found to improve the catalytic activity. The maximum reaction rate of the hydrogen peroxide-mediated 3,3',5,5'-tetramethylbenzidine reaction in the presence of ssDNA–g-C$_3$N$_4$ nanosheets was at least four-fold faster than pure g-C$_3$N$_4$ nanosheets. Considering this advantage, aptamer CD63 was introduced to specifically target EVs and generate variable catalytic ability (decrement) based on the varying concentrations (increment) of EVs. The EVs concentration was quantified by the color change of the product, and the LOD was calculated to be down to $13.52 \times 10^5$ EVs/mL. A similar signal trend was also observed from EVs collected from the sera samples. The developed system could also be used to characterize the differential expression of exosomal CD63 between the breast cancer cell line (MCF-7) and a control cell line (MCF-10A). Xia et al. quantified EVs based on aptamer-CD63-functionalized single-walled carbon nanotubes (s-SWCNTs) [56]. As the functionalization with ssDNA exhibited enhanced peroxidase activity of s-SWCNTs, the addition of EVs resulted in a decrement of catalytic ability and a color change as well. The LOD was $5.2 \times 10^5$ EVs/$\mu$L, which was 10-fold lower than the commercial ELISA. Similar to this, Chen et al. detected prostate cancer EVs by integrating EpCAM aptamer on iron oxide (Fe$_3$O$_4$) NPs, which also possess peroxidase
Prior to the detection of the EV, an anion exchange-based isolation (with magnetic beads) was performed to collect EVs from plasma and cell culture medium. Through the suggested method, the EVs were isolated with >90% efficiency and presented fewer protein impurities compared with ultracentrifugation. Applying the EpCAM aptamer–Fe₃O₄ NPs for colorimetric detection of prostate cancer EVs revealed a linear range from $0.4 \times 10^8$ to $6.0 \times 10^8$ EVs/mL and an estimated LOD of $3.58 \times 10^6$ EVs/mL.

Instead of using the catalytic property of nanomaterials, Jiang et al. reported a multiplexed EV sensing system based on the inherent optical properties of Au NPs [58]. The sensor system was composed of Au NPs complexed with a panel of aptamers. The surface capped with aptamers protected the Au NPs against aggregation/agglomeration in a high-salt solution and helped to maintain the colloidal stability. When EVs are presented, the stronger binding between the aptamer and targeted surface protein EV dominates over the non-specific binding between aptamers and the Au NPs. Subsequent electrostatic aggregation/agglomeration of Au NPs occurs, and the solution changes from red to blue because of the detachment of the aptamer from the surface of Au NPs. By employing this simple approach, the differential expression of surface proteins (CD63, EpCAM, platelet-derived growth factor, prostate-specific membrane antigen, protein tyrosine kinase-7) was investigated in EVs derived from human cervical carcinoma (HeLa), human acute lymphoblastic leukemia (Ramos), human prostate cancer (PC3) and human acute lymphoblastic leukemia (CEM) cells. Liu et al. detected EV released from nasopharyngeal carcinoma cells by applying a simple approach [59]. This system employed two proximity-ligation-assay probes to generate a unique surrogate DNA signal for EV detection. The DNA signal was multiply amplified by transcription-mediated amplification united with recombinase polymerase amplification and quantitatively detected by colorimetric assay using Au NPs. Through this multiple amplification, plasma Epstein–Barr virus latent membrane protein 1-positive (accuracy: 0.956) and EGFR-positive (accuracy: 0.906) EV levels in patients were investigated. This colorimetric sensor showed a LOD of $10^2$ EVs/mL and a wide dynamic range of $10^2$–$10^8$ EVs/mL.

As an alternative approach, a nanotechnology-based fluorescence biosensor has been considered as a notable and popular detection technique with high sensitivity and selectivity [60]. For example, various nanomaterials, including two-dimensional nanomaterials, metal oxide NPs, up-conversion nanoparticles (UCNPs) and metallic NPs, have been employed in optical biosensors based on their distinctive optical properties [21,60]. Jin et al. constructed a fluorescence resonance energy transfer-mediated biosensing system based on an aptamer and graphene oxide (GO) to quantify prostate cancer EVs (Figure 2C) [55]. Owing to the complete atomic-thick layers and abundant terminal groups, GO exhibited a high affinity for the target-responsive fluorescent aptamer and intrinsic fluorescence quenching ability to form a quenched aptamer–GO nanoprobe. When the EVs are presented, the aptamer preferentially binds with EVs and restores the fluorescent signal via detachment from GO. In addition, the exposed aptamer sequence can be digested by deoxyribonuclease-I, so that the targeted surface protein of the EV can be recycled to amplify the fluorescence signal. As a result, the LOD achieved was $1.6 \times 10^5$ EVs/mL. Furthermore, by modulating seven different aptamers (CD63, EpCAM, prostate-specific membrane antigen, protein tyrosine kinase-7, carcinoembryonic antigen, platelet-derived growth factor), the expression level on EVs derived from serum samples of prostate cancer patients and healthy individuals. Taking advantage of the similar absorption property of GO, Zhang et al. constructed a biosensing platform based on the Cy3-labeled aptamer-CD63 and Ti₃C₂ MXenes complex for EVs detection [61]. The selective adsorption of Cy3-labeled aptamer-CD63 on Ti₃C₂ MXenes via hydrogen bond and metal chelate interaction results in a fluorescence quenching of the labeled Cy3 dye. When EVs are presented, the fluorescent Cy3 label is recovered because of the relatively stronger affinity between the aptamer and EV. The linear range was estimated to be $10^4$–$10^9$ EVs/mL, and the LOD was $10^2$ EVs/mL. Chen et al. developed a simple paper-supported biosensor based on luminescence resonance energy transfer from UCNPs to Au nanorods for EV detection [62]. Here, two aptamer fragments were designed to bind with the CD63 protein on the surface of EVs and recruit Au nanorods near the UCNPs, which initiates the luminescence quenching
of the green fluorescence of UCNPs. As a result, the quenched fluorescent signal linearly correlated to the concentration range of $1.0 \times 10^4$–$1.0 \times 10^8$ EVs/µL and reached a LOD of down to $1.1 \times 10^3$ EVs/µL.

Lee et al. developed a selective and sensitive system to detect exosomal miRNA (Figure 2D) by using the quenching and recovery of fluorescence mechanism, as well as the metal-enhanced fluorescence of a multifunctional single nanorod structure with magnetic and plasmonic components [63]. Each component was specifically modified to selectively isolate targeted EVs through magnetic immunoseparation and sensitively and selectively identify targeted exosomal miRNA using a fluorophore-labeled hairpin single-stranded molecular beacon. The fluorescence signal from the miRNA–magnetic bead complex could be enhanced through metal-enhanced fluorescence effects at the Au component area of the multifunctional nanorod. Interestingly, this system was used to characterize the neurogenesis of stem cells, as well as a heterogeneous population of neural cells in an ex vivo rodent model, which indicates the importance of EVs in applications other than disease monitoring. Similarly, He et al. presented a copper-mediated fluorescent signal amplification strategy for EV detection [64]. Cholesterol-modified magnetic beads captured EVs via hydrophobic interactions between cholesterol moieties and lipid membranes. Subsequently, sandwich complexes were formed by aptamer-CD63-modified copper oxide (CuO) NPs. The consequential sandwich complexes are liquified by acidolysis to transform CuO NPs into copper (II) ions (Cu^{2+}) and Cu^{2+} can be reduced to form fluorescent Cu NPs in the presence of sodium ascorbate and polythymine. As the fluorescence of Cu NPs is directly proportional to the concentration of Cu^{2+} and EVs, quantitative analysis was achieved in the range of $7.5 \times 10^4$–$1.5 \times 10^7$ EVs/µL and LOD of $4.8 \times 10^4$ EVs/µL in complex biologic fluids. Recent studies of colorimetry- and fluorescence-based analytical methods for EV detection are compared in Table 2.
Table 2. Comparison of Colorimetric/Fluorescence-Based Bionano Sensors for EV Detection.

| Method                                      | Working Principle                                                                 | Target                              | Correlation Range          | Detection Limit       | Ref  |
|---------------------------------------------|-----------------------------------------------------------------------------------|-------------------------------------|-----------------------------|-----------------------|------|
| Colorimetric                                | ZnO-nanowires-coated three-dimensional (3D) scaffold chip                         | Breast cancer (MCF-7)               | $2.2 \times 10^3$–$2.4 \times 10^7$ EVs/µL | $2.2 \times 10^3$ EVs/µL | [52] |
|                                             | Microfluidic chip with self-assembled three-dimensional herringbone nanopatterns (nano-HB) | Ovarian cancer                      | $1 \times 10^3$–$5 \times 10^5$ EVs/µL | 10 EVs/µL            | [53] |
|                                             | Graphitic carbon nitride nanosheets (g-C3N4 NSs)                                  | Breast cancer (MCF-7)               | $0.19 \times 10^9$–$3.38 \times 10^7$ EVs/µL | $1.352 \times 10^3$ EVs/µL | [54] |
|                                             | Aptamer-CD63 functionalized single-walled carbon nanotubes (s-SWCNTs)             | Breast cancer (MCF-7)               | $1.84 \times 10^6$–$2.21 \times 10^7$ EVs/µL | 5.2 $\times 10^2$ EVs/µL | [56] |
|                                             | EpCAM aptamer modified Fe$_3$O$_4$ NPs                                            | Prostate cancer                     | $0.4 \times 10^5$–$6.0 \times 10^5$ EVs/µL | 3.58 $\times 10^3$ EVs/µL | [57] |
|                                             | Au NPs complexed with a panel of aptamers                                        | Prostate cancer                     | 0–12.8 µg/mL                | Not stated            | [58] |
|                                             | PLA–RPA–TMA assay                                                                 | Nasopharyngeal carcinoma cell       | 0.1–$10^5$ EVs/µL          | 0.1 EVs/µL           | [59] |
| Fluorescence                                | Fluorescent labeled aptamer/GO nanoprobe                                         | Prostate cancer                     | $1.6 \times 10^5$–$1.6 \times 10^7$ EVs/µL | $1.6 \times 10^5$ EVs/µL | [65] |
|                                             | Cy3 labeled aptamer–CD63 and Ti$_3$C$_2$ MXenes complex                           | Melanoma (B16), Breast cancer (MCF-7), ovarian carcinoma (OVCAR-3), liver cancer (Hep G2) | $10$–$10^6$ EVs/µL       | 0.1 EVs/µL            | [61] |
|                                             | Aptamer modified UCNPs and Au NRs                                                 | Liver cancer (Hep G2)              | $1.0 \times 10^4$–$1.0 \times 10^6$ EVs/µL | $1.1 \times 10^5$ EVs/µL | [62] |
|                                             | Multifunctional magneto-plasmonic NRs                                             | Neurogenesis(miR-124)              | 1 Pm–$10^6$ pM              | 1 Pm                  | [63] |
|                                             | Copper-mediated fluorescent signal amplification                                 | Cancer (Hep G2)                    | $7.5 \times 10^4$ to $1.5 \times 10^7$ EVs/µL | $4.8 \times 10^4$ EVs/µL | [64] |
4. Electrochemical-Based Analysis Methods for EV Detection

Electrochemical biosensors hold prodigious potential in the biomedical field because of their high specificity, sensitivity, label-free and cost-effectiveness for detecting several biomarkers of diseases [66-69]. These devices contain biologic recognition elements with electrochemical signaling molecules such as enzymes [70], antibodies with electro-active molecules [71] and nucleic acids with electro-active molecules [72] that selectively responds with the target biomolecules and produces an electrical signal that is related to the concentration of the target analyte. In an electrochemical biosensor, the transducer translates biologic events, such as an immune reaction or a nucleic acid hybridization, into an electrical signal. There are representative analytical methods for the detection of biologic events, which are amperometry, potentiometry, voltammetry and impedance spectroscopy [73,74]. Among them, amperometry measures the change of current with constant potential, whereas potentiometric analysis converts biologic events to the equilibrium potential difference. In addition, voltammetry was shown the current change with varying voltages. These strategies utilized the reduction and oxidation of the specific redox materials, whose redox properties could be changed due to the biologic reaction. Owing to this phenomenon, electrochemical biosensors operate extensively in disease diagnostics for the detection of suitable markers, including EVs, proteins and nucleic acids. In addition, electro-active nanomaterials have been applied to electrochemical biosensors for improving the performance, including sensitivity and specificity. This section discusses current studies on nanotechnology-integrated electrochemical biosensors for the measurement of EVs and EV-related biomarkers.

Among the several types of electrochemical biosensor for the detection of EVs, immunosensors, represented by ELISA, have been well-studied because of their inherent specific detection property. Doldan et al. exhibited the electrochemical sandwich immunosensor by using a surface marker-mediated signal amplification of down to four orders of magnitude compared with conventional ELISA (Figure 3A) [75]. Each EV has various surface markers, such as CD9 and CD63, detectable by the enzyme-tagged antibodies. The number of surface markers on the EV should proportionally exceed that of the EVs. In this context, the authors demonstrated the highly sensitive amperometric detection of EVs by measuring the electrochemically signal of HRP tagged to anti-CD9 [72]. The developed electrochemical biosensor measured EVs with a dynamic range of $2 \times 10^2$–$1 \times 10^6$ particles/µL and could reliably quantify EVs in >1000-fold dilutions of human blood plasma. Cao et al. developed an amplified electrochemical biosensing system for human hepatoma (HepG2)-derived EV detection [76]. To amplify the electrochemical signal, the target EVs are concentrated on an anti-CD63-functionalized magnetic bead by magnetic separation and captured by a CD63 aptamer, which triggers a catalytic molecule machine that is dependent on a cascade toehold-mediated strand displacement reaction. The LOD of this system is $1.72 \times 10^4$ particles/mL, with a linear range from $1 \times 10^5$ to $5 \times 10^7$ particles/mL. Moura et al. presented an electrochemical biosensor for EVs preconcentrated by immunomagnetic separation on anti-CDX-modified magnetic particles (CDX being CD24, CD44, CD54, CD326 or CD340), followed by labeling with the anti-CD63–HRP antibody as an electrochemical probe [77]. The EVs were derived from three breast cancer cell lines (MCF-7, SK-BR-3 and MDA-MB-231), and the specific receptors of the cancer-derived EVs were targeted by their respective antibodies. The developed electrochemical immunosensor reached a LOD of $10^5$ EVs/µL in human serum while avoiding the interference from free receptors in the serum matrix. An et al. developed a magneto-mediated electrochemical sensor based on host–guest recognition for the simultaneous analysis of breast cancer exosomal proteins [78]. CD63-aptamer-modified magnetic beads were used initially to capture the EVs. The expression levels of four proteins (mucin 1, human epidermal growth factor receptor 2, EpCAM and carcinoembryonic antigen) on the breast cancer patient-derived EVs were measured by using silica (Si) NPs modified with the respective aptamers and functionalized with a mercapto-ferrocene derivative. The sandwich structure (magnetic beads–EVs-Si NPs) was separated by a magnet and dissociated by adding agents that reduce disulfide bonds. A GO-cucurbit modified carbon electrode was then employed to measure the oxidation current signals, proportional to the quantity of EV. Results
obtained from a clinical test of this approach confirmed higher levels of all four exosomal proteins in serum from a breast cancer patient compared with a healthy individual. The LOD was $1.2 \times 10^3/\mu L$.

Figure 3. electrochemical biosensor for EV detection. (A) Schematic diagram of the electrochemical sandwich immunoassay with an enzyme for measurement of EVs; (B) electrochemical aptamer-based sensor using DNA nanotetrahedron as a capture moiety on the electrode; (C) hemin/G-quadruplex-assisted signal amplification for sensitive electrochemical detection of EVs from gastric cancers; (D) signal amplification strategy for electrochemical EV detection by using hairpin DNA-functionalized silver nanoparticles. (reproduced with permission from [75], published by American Chemical Society 2016, reproduced with permission from [79] published by American Chemical Society 2017, reproduced with permission from [80] published by WILEY-VCH 2019 and reproduced with permission from [81] published by Elsevier 2020).

Besides the immunoaffinity-based methods, numerous studies have used an aptamer-based electrochemical sensor for EV detection. Wang et al. developed a nanotetrahedron-assisted aptasensor for capturing and detecting the surface proteins of hepatocellular EVs (Figure 3B) [79]. The oriented immobilized aptamers on the DNA nanotetrahedron improved the accessibility of the aptamer to EVs, providing an aptasensor with 100-fold higher sensitivity ($10^4/mL$) when compared with the single-stranded aptamer-functionalized aptasensor ($10^6/mL$). Dong et al. described a new strategy for EV detection based on aptamer recognition-induced multi-DNA release from magnetic particles and cyclic enzymatic amplification [82]. The multi-DNA release was triggered by the EV-aptamer interaction. Subsequent enzymatic degradation by Exo III exonuclease of functionalized DNA immobilized on the electrode turned the electrochemical signal off. The electrochemical signal reflected the concentration of the electro-active molecules—and this correlated with the multi-DNA concentration, which correlated with the EV concentration. As a result of the catalytic property of the Exo III exonuclease, a low LOD of 70 particles/$\mu L$ was achieved, thereby demonstrating ultrasensitive detection with high selectivity. Huang et al. exhibited a label-free electrochemical aptasensor for the specific detection of gastric cancer EVs (Figure 3C) [80]. An anti-CD63-functionalized Au electrode captured the gastric cancer-derived EVs, and a specific gastric cancer EV aptamer with a G-quadruplex circular template triggered rolling circle amplification, producing multiple G-quadruplex units with HRP mimicking DNAzyme property. The aptasensor showed high selectivity and sensitivity of gastric cancer EVs and a LOD of $9.54 \times 10^2/mL$. The electrochemical biosensor developed by An et al. was based on click chemistry of alkynyl-4-ONE and the DNA hybridization chain reaction (HCR) to amplify the signal by using a streptavidin–biotin reaction for the determination of tumor EVs [83].
The EV concentration was quantified in the range of $1.12 \times 10^2 – 1.12 \times 10^8$ particles/$\mu$L by monitoring the electrochemical reduction current of 2,3-diaminophenazine generated from the oxidation of o-phenylenediamine by hydrogen peroxide. Zhao et al. developed an ultrasensitive electrochemical biosensor for the detection of EVs by coupling a 3D DNA walking machine, consisting of two specific DNA aptamers, with Exo III-assisted recycling [84]. Breast cancer cells (MCF-7) were detected with high sensitivity (1.3 $\times$ $10^4$ particles/mL) and specificity. In comparison, Yin et al. reported a slightly lower LOD of 1.2 $\times$ $10^4$ particles/mL by using an aptamer recognition-triggered label-free electrochemical biosensing method with Exo III-assisted signal amplification for highly selective and ultrasensitive detection of MCF-7-derived EVs [85]. The authors claimed that it could be shown the outstanding properties of simplicity, rapidness, cost-efficiency and easy manipulation.

Small non-coding RNAs, such as miRNA, are altered in cancers, suggesting that miRNAs could be reliable cancer biomarkers [86–88]. Therefore, electrochemical sensors have been also developed for the measurement of exosomal miRNAs. Boriachek et al. selectively isolated exosomal miRNAs from complex biological samples using magnetic beads pre-hybridized with biotinylated complementary probes and then directly capturing the exosomal miRNAs on the working electrode [89]. This amplification-free electrochemical biosensor displayed good reproducibility (% relative standard deviation [RSD] of <5.5), sensitivity (LOD of 1 pM) and dynamic range (1 pM–100 nM)) from various cancer cell lines and serum samples collected from patients with colorectal adenocarcinoma. Luo et al. exhibited a ratiometric electrochemical biosensor by using a locked nucleic acid (LNA)-modified electrode for the detection of exosomal miR-21, released by MCF-7 cancer cells [90]. The polylysine film-coated glassy carbon electrode was functionalized by a “Y”-shaped LNA, and the target exosomal miR-21 induced a conformational change in the “Y”-shaped LNA to the molecular beacon, which increases the redox peaks. This simple DNA structural transformation could detect exosomal miR-21 with a LOD as low as 2.3 fM. Guo et al. showed a sensitive electrochemical assay of miR-122 by HCR of the hairpin structure of the capture DNA on the surface of the electrode [91]. The miR-122 opened the hairpin DNA and triggered the HCR through the cross-opening and hybridization of two helper DNA hairpins. HCR induced the formation of long nicked double helices, which captured the electro-active molecule and increased the electrochemical signal. The LOD for miR-122 detection was greatly improved to 53 aM offered high reproducibility. Cheng et al. developed an enzyme-free electrochemical biosensor for the detection of exosomal miRNAs by the double signal amplification strategy (Figure 3D) [81]. Ultraselective detection was achieved through a cyclic signal amplification method with the target miRNA (miR-21) and subsequent immobilization of silver (Ag) NPs on the electrode by a streptavidin–biotin interaction. A low LOD of 0.4 fM miR-21 in human biologic samples was demonstrated. Recent studies of electrochemical-based analytical methods for EV detection are compared in Table 3.
Table 3. Comparison of Electrochemical Bionano Sensors for EV Detection.

| Method | Working Principle | Target | Correlation Range | Detection Limit | Ref |
|--------|-------------------|--------|-------------------|-----------------|-----|
|       | Electrochemical sandwich immunosensor (amperometry) | Breast cancer (MCF-7) | $2 \times 10^2$–$1 \times 10^6$ EVs/µL | $2 \times 10^5$µL | [75] |
|       | Cascade toehold-mediated strand displacement reaction (CTSDR) (voltammetry) | Liver cancer (HepG2) | $1 \times 10^3$ to $5 \times 10^5$ EVs/µL | $1.72 \times 10^2$µL | [76] |
|       | Electrochemical immunosensor using magnetic bead (amperometry) | Breast cancer (MCF7, MDA-MB-231 and SK-BR-3) | $1 \times 10^2$–$1 \times 10^6$ EVs/µL | $10^2$µL | [77] |
|       | Electrochemical sensor based on graphene oxide-cucurbit modified carbon electrode (voltammetry) | Breast cancer (MCF-7, SK-BR-3, MDA-MB-231 and BT474) | $1.2 \times 10^2$–$1.2 \times 10^7$ EVs/µL | $1.2 \times 10^3$µL | [78] |
|       | Electrochemical aptasensor using DNA nanotetrahedron and aptamer (voltammetry) | Liver cancer (HepG2) | $1 \times 10^2$–$1 \times 10^5$ EVs/µL | $10^2$µL | [79] |
|       | Electrochemical aptasensor by cyclic enzymatic amplification (voltammetry) | Prostate cancer and breast cancer (LNCaP and MCF-7) | 70 to $1 \times 10^5$ EVs/µL | 70µL | [82] |
| Electrochemical | G-quadruplex circular template triggered rolling circle amplification (RCA) for electrochemical sensor (voltammetry) | Gastric cancer (GES-1 and SGC7901) | $0.954$–$7.8 \times 10^2$ EVs/µL | $0.954$µL | [80] |
|       | Electrochemical biosensor based on click chemistry of alkynyl-4-ONE (voltammetry) | Breast cancer (MCF-7) | $1.12 \times 10^2$–$1.12 \times 10^5$ EVs/µL | $1.12 \times 10^2$µL | [83] |
|       | Electrochemical biosensor by coupling the DNA walking machine (voltammetry) | Breast cancer (MCF-7) | $13$–$1.0 \times 10^7$µL | 13µL | [84] |
|       | Exo III-assisted cycling reaction for signal amplification (voltammetry) | Breast cancer (MCF-7) | $12$–$3.4 \times 10^5$ EVs/µL | $12$µL | [85] |
|       | Electrochemical detection of exosomal miRNAs by using magnetic separation (voltammetry) | miR-21 | $1 \text{ pM–100 nM}$ | $1 \text{ pM}$ | [89] |
|       | Electrochemical biosensor by Y-shaped locked nucleic acid (LNA) (voltammetry) | miR-21 | $10.70$–$2.3 \text{ fM}$ | $2.3 \text{ fM}$ | [90] |
|       | Electrochemical assay of miR-122 by hybridization chain reaction (HCR) (voltammetry) | miR-122 | $1 \times 10^2$–$1 \times 10^3$ aM | $53 \text{ aM}$ | [91] |
|       | Enzyme-free electrochemical biosensor by the double signal amplification strategy (voltammetry) | miR-21 | $1 \text{ fM–200 pM}$ | $0.4 \text{ fM}$ | [91] |
5. Raman-Based Analysis Methods for EV Detection

Raman spectroscopy is an optical analysis that measures the intensity of the inelastic scattering of the incident light to gather information about the chemical structures in individual molecules [92,93]. Raman spectra can be shifted along with the chemical structure of each molecule and specific Raman shifts can be used as a fingerprint of each molecule. Specific signals in Raman spectra can also be utilized as specific redox peaks in electrochemical biosensors, for determining the concentration of the target. Nonetheless, the Raman shift of typical biomarkers shows weak signal intensity, which necessitates biomedical applications, such as point-of-care testing or early diagnosis. Alternatively, surface-enhanced Raman scattering (SERS), which enhances the Raman signal intensity by a magnitude of $10^{14}$ because of the surface plasmon effects on the surface of metal nanomaterials, could overcome the limitation of low-intensity of Raman signals [94–96]. This section briefly introduces recent studies related to SERS-based exosomal detection platforms.

For the capture and detection of EVs using Raman-based biosensors, the antibody-mediated immunoassay is one of the representative methods. Tian et al. exhibited a highly sensitive scattering SERS-based EV biosensor by combining SERS nanoprobes and portable Raman devices (Figure 4A) [97]. In this immunosensor system, Au nanostar@4-mercaptopenzoic acid@nanoshell structures functionalized with a bivalent cholesterol-labeled DNA were utilized as a Raman probe. The targeted EVs were immunomagnetically captured by anti-CD9-functionalized magnetic beads. Afterward, the SERS nanoprobes (Au nanostar@4-mercaptopenzoic acid@nanoshell) were anchored to the EV membrane through hydrophobic interactions. The LOD of this SERS-biosensor was 27 particles/µL. The authors claimed that the developed biosensor was easily fabricated and had considerable potential for early diagnosis, among various other applications. Kwizera et al. exhibited a miniaturized affinity-based SERS-sensitive device to capture and analyze EVs in a target-specific manner with the assistance of low-cost 3D printing technology [98]. QSY21-coated Au nanorods were used as Raman reporters to quantitatively detect the surface marker on the EVs derived from HER2-positive breast cancer. This analytical platform provides precise detection with a LOD of $2 \times 10^6$ EVs/mL and evaluates over 80 samples within 2 h, simultaneously. Zhang et al. developed a SERS-based EV profiling platform for simultaneous measurement and detection of multiple EV membrane proteins, including glypican-1 [99], EpCAM and CD44 variant isoform 6 (CD44V6), isolated from pancreatic carcinoma cells. For the capture and probe of specific EVs, diverse antibody-functionalized Au NPs were applied to the medium containing the EVs. This highly sensitive SERS platform measured as low as $2.3 \times 10^6$ particles/mL in a small sample (10 µL) and showed high specificity profiling of the three biomarkers. In addition, phenotypic profiling of EVs from colorectal cancer, pancreatic cancer and bladder cancer cell lines (SW480 and C3) was conducted that successfully classified the EVs in both phosphate-buffered saline and plasma. Pang et al. developed a SERS immunoassay for the capture and analysis of exosomal programmed death ligand 1 (PD-L1), which is a predictor for antiprogrammed death-1 therapy [100]. Anti-PD-L1-functionalized Fe$_3$O$_4$@TiO$_2$ NPs were used to capture and separate the specific EVs by magnetic force and the Au@Ag@4-mercaptopenzoic acid nanoprobe for SERS analysis was bound to the EV as a sandwich immunoassay. Exosomal PD-L1 could be measured with a LOD of 1 PD-L1 EV/µL in 4 µL of undiluted serum within 40 min.
Figure 4. Raman-based biosensor for EV detection. (A) Sequential surface-enhanced Raman scattering (SERS)-based assay process for the detection of EVs by using SERS nanoprobes (AuNS@4-MBA@Auanchor); (B) multiple detections of cancer EVs through aptamer-functionalized Au nanoparticle and magnetic bead; (C) aptamer-functionalized Au nanoparticles in a triangular pyramid for the signal amplification of SERS biosensor for EV detection (D) duplex-specific nuclease (DSN)-assisted SERS signal amplification for quantitative detection of exosomal miRNA using Au@Ag–Au alloy shell nanoparticles. (Reproduced with permission from [97], published by the royal society of chemistry 2018, reproduced with permission from [101] published by the royal society of chemistry 2018, reproduced with permission from [102] published by American Chemical Society 2019 and reproduced with permission from [103] published by Elsevier 2018).

Aptamer-based EV detections by SERS analysis were also developed recently. Wang et al. demonstrated a SERS-based method for the detection of multiple EVs by using a magnetic bead-coated Si shell and Au (methylene blue@SiO$_2$@Au) decorated with the aptamer of a generic surface protein, CD63 (Figure 4B) [101]. The LOD was 32, 73 and 203 EVs/µL for breast cancer (SK-BR-3), colorectal cancer (T84) and prostate cancer (LNCaP) EVs, respectively. Based on the results, the proposed SERS-based biosensor with aptamer is promising to diagnose early stage cancers. Zhang et al. developed a novel Raman probe composed of Au NPs and triangular pyramid DNA for the sensitive detection of circulating tumor cells and EVs (Figure 4C) [102]. Triangular pyramid DNA could induce electromagnetic hot spots, where an intense electromagnetic effect through the triangular arrangement of three AuNPs is. As a result, 5–100,000 cells/mL of HeLa cells could be detected in 1.0 × 10^6 cells/mL HEK-293T cells without the enrichment process. For the EV, the LOD was 1.1 × 10^2 particles/µL with high specificity, and the assay performed well in plasma samples. Zhu et al. described a sensitive aptasensor by using a hydrophobic-assembled nanoacorn (HANA) with Au@Ag nanocubes as a Raman probe [104]. Exosomal proteins, including CD63, HER2 and EpCAM, could bind to the aptamers on the surface of HANA, and the Au@Ag nanocube attached to the vacant HANA through electrostatic interactions. This well-oriented distribution of SERS probes confirms outstanding repeatability, whereas the accurate sub-nanometer junctions assure high sensitivity. Measurement of HER2 was highly sensitive and reproducible (RSD < 7%), and EVs were detected at 50 EVs/µL with a low RSD of 6.4% [104]. Ning et al. developed a reliable SERS sensor for the simultaneous detection of multiple cancer-related EVs [105]. The SERS probes consisted of Au–Ag–Ag core–shell–shell nanotrepangs (GSSNTs) and functionalized DNA with a bumpy structured surface. With three different Raman probe-modified GSSNTs, multiple EVs from different cancer cell lines (LNCaP, SK-BR-3 and HepG2) were successfully measured with
high sensitivity and excellent multiplexed detection capacity. The quantitative detection of every single EV showed a linear correlation ranging from 1 to $10^4$ particles/µL.

Exosomal miRNAs can also be measured by the Raman-based analytical methods with suitable nanomaterials for signal enhancement. Ma et al. exhibited a SERS-based exosomal miRNA sensor with duplex-specific nuclease-assisted signal amplification and Au@R6G@AgAu NPs, where R6G is rhodamine 6G, as a strong Raman reporter (Figure 4D) [103]. Au@R6G@AgAu NPs were connected to Si microbeads through the DNA capture probe, which could be complimentarily bound to the target miRNA. If the target miRNA binds to the DNA capture probe, Au@R6G@AgAu is dissociated from the Si microbead by the duplex-specific nuclease, and the SERS signal is increased proportionally to the exosomal miRNA level. The LOD was just 5 fM, and the method could differentiate the patients from healthy individuals, showing a more than six-fold difference in the signal. Lee et al. developed a uniform plasmonic head-flocked Au nanopillar substrate for the signal enhancement of SERS by providing multiple hotspots [106]. Two different LNAs captured and detected the target miRNA with Cy3 labeling. Using this Au nanopillar array, an extremely low detection of three different miRNAs (miR-21, -222 and 200c) was achieved with a wide dynamic range (1 aM–100 nM). In addition, a reliable expression pattern of exosomal miRNA from breast cancer cell lines was obtained, and different breast cancer subtypes could be differentiated. Recent studies of Raman-based analytical methods for EV detection are compared in Table 4.
Table 4. Comparison of Raman-Based Bionano Sensors for EV Detection.

| Method                                                                 | Working Principle                                                                                     | Target                                                                 | Correlation Range          | Detection Limit          | Ref   |
|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------|--------------------------|-------|
| Raman SERS-based immunosensor by gold nanostar@4-mercaptobenzoic acid@nanoshell structures | Liver cancer (HepG2)                                                                                | 40–4 × 10^7 EVs/µL                                                    | 27/µL                      | [97]                     |
| Miniaturized affinity-based SERS-sensitive device by 3D printing        | Breast cancer (MDA-MB-231, MDA-MB-468 and SK-BR-3)                                                    | 10^6–10^8 EVs/µL                                                     | 2×10^3/µL                  | [98]                     |
| SERS-based EV profiling platform using surface proteins                | Colorectal cancer and bladder cancer (SW480 and C3)                                                 | 2.3 × 10^5–2.3 × 10^8 EVs/µL                                         | 2.3×10^3/µL                | [99]                     |
| Raman SERS immunoassay using anti-PD-L1-functionalized Fe3O4@TiO2 nanoparticles | Lung cancer (A549)                                                                                   | 5–2 × 10^2 EVs/µL                                                    | 1/µL                       | [100]                    |
| SERS-based multi-EV detection by MB@SiO2@Au nanoparticle               | Breast cancer and prostate cancer (SK-BR-3, T84 and LNCaP)                                           | 32–3.2 × 10^5 EVs/µL                                                 | 32/µL                      | [101]                    |
| SERS-based aptasensor by Au nanoparticles and triangular pyramid DNA  | Breast cancer and cervical cancer (MCF-7, Hela and HEK-293 T)                                       | 1.0 × 10^5–1.0 × 10^7 EVs/µL                                         | 1.0 × 10^3/µL              | [102]                    |
| SERS biosensor with hydrophobic assembled nanoacorn and Au@Ag nanocubes| Breast cancer (MCF7, MBA-MD-231)                                                                     | 50–1.0 × 10^6 EVs/µL                                                 | 50/µL                      | [104]                    |
| SERS aptasensor by gold–silver–silver core–shell–shell nanotrepangs    | Breast cancer, prostate cancer and liver cancer (SK-BR-3, HepG2 and LNCaP)                           | 1–10^4 EVs/µL                                                        | 1/µL                       | [105]                    |
| SERS-based sensor with duplex-specific nuclease (DSN) and Au@R6G@AgAu nanoparticles | miR-21                                                                                                | 5 fM–20 pM                                                           | 5 fM                       | [103]                    |
| Uniform plasmonic head-flocked gold nanopillar substrate for the signal enhancement of SERS | miR-21, 222, 200c                                                                                   | 1 aM–100 nM                                                          | 1 aM                       | [106]                    |
6. Conclusions and Future Perspective

This review article focused on biosensors that integrate nanotechnology with diverse analytical methods, including SPR-, fluorescence-, electrochemical- and Raman-based strategies for the effective measurement of EVs as biomarkers in diagnosing several diseases. Due to the inherent properties of nanomaterials (high surface-to-volume ratio, high reactivity and signal-enhancing effect), the precise and sensitive detection of EVs could be demonstrated. In addition, specific properties and multifunctionalities of each nanomaterial could facilitate the efficient measurement of EVs present in real samples. Most of the presented EV biosensors showed improved sensitivity by using functionalized nanomaterials and unique strategies. Besides the four representative analytical methods, others, such as field-effect-transistor [107,108], mechanical changes using a cantilever or quartz crystal microbalance [109–111] and giant magnetoresistance [112] could also be integrated with nanotechnologies to measure EVs. In this context, nanotechnology-integrated detection systems could be expanded to diverse analytical methods. In addition, label-free detection of EV can be developed by exploiting the high sensitivity of nanomaterials. One study presented a nanogap-integrated plasmonic sensing platform for EV detection without a Raman probe labeling step [113]. For improving the sensitivity, they used nanogap combining sub-volt dielectrophoretic trapping and Au NPs for real-time SERS imaging. Another study fabricated graphene-functionalized Au nanopyramids on SiO$_2$ and successfully characterized EVs isolated from different biologic sources using unbiased principal component analysis [114].

Besides detecting EVs by their specific surface proteins, encapsulated biomolecules, such as miRNA, mRNA and protein, could be important biomarkers for the diagnosis of diseases. Some exosomal miRNAs have been utilized as cancer biomarkers [115–117]. However, the expression levels of one miRNA could not indicate the presence of diseases precisely. Therefore, profiling of exosomal miRNA or other biomolecules will be more important for obtaining precise and personalized information, as well as diagnostic information or drug sensitivity. To this end, the isolation, rupture, and other pretreatment steps should be integrated into the sensing platform for collecting the encapsulated biomolecules efficiently. A powerful tool to leverage the functionality of biosensors is artificial intelligence-driven multi-technology bioprinting systems. On this wise, isolation, rupture, and other pretreatment steps should be integrated on the sensing platform for collecting the encapsulated biomolecules efficiently, as well as detection of the EV itself precisely. EV presents in diverse body fluids, such as blood, saliva, urine and interstitial fluids. For efficient measurement of EV in several real samples, preparation steps are very important to prevent pulse-positive signals and reduce trivial noise. Therefore, integrated platforms of sample preparation, detection, and analysis modules will be further developed with various nanotechnology to improve their performances. The concept of “organ-on-a-chip” is emerging for the etiology and drug screening of several diseases. For efficient drug testing, EV biosensors as a sensing module can provide real-time monitoring and fast response to the drugs on disease-emulated “organ-on-a-chip.” Currently, “organ-on-a-chip” operates as a proxy for in vitro and in silico research.

In conclusion, nanotechnology can be combined with EV biosensors to improve sensing capabilities, such as high selectivity, high sensitivity, straightforward and rapid detection, multi-detection and in situ monitoring. Here, we report the present status in the integration of nanotechnology-based biosensor platforms and analytical methods (SPR-, fluorescence-, electrochemical-based and Raman-based measurements) for detecting EVs. Each method has unique properties and suitable nanotechnologies are effortlessly utilized to improve the sensing performances. On this wise, isolation, rupture, and other pretreatment steps should be integrated on the sensing platform for collecting the encapsulated biomolecules efficiently, as well as detection of the EV itself precisely. EV presents in diverse body fluids, such as blood, saliva, urine and interstitial fluids. For efficient measurement of EV in several real samples, preparation steps are very important to prevent pulse-positive signals and reduce trivial noise. Therefore, integrated platforms of sample preparation, detection, and analysis modules will be further developed with various nanotechnology to improve their performances. In the immediate future, it is expected that micro total analysis systems and advanced “organ-on-a-chip” platforms...
with nanomaterial-based sensing modules for EVs will provide a robust in vitro drug development in platforms that can replace in vitro cell culture models and in vivo animal models and enable in vitro personalized investigations. Recently, multifunctional nanomaterials have been exploited to possess remarkable properties, such as enhancement of electron transfer reactions and improvement of quantum yield, for sensitive detection of optical properties. The development of nanotechnology will offer innovative and creative directions to develop novel biosensing platforms for EVs to increase the full recovery rate of diseases through the early diagnosis at a low level of exosomal biomarkers in real samples.

**Author Contributions:** Conceptualization, J.-H.C., J.-H.L. and J.-W.C.; investigation, J.-H.C. and J.-H.L.; resources, J.-H.C. and J.-H.L.; writing—Original draft preparation, J.-H.C. and J.-H.L.; writing—Review and editing, J.-H.C. and J.-H.L.; supervision, J.-W.C.; project administration, J.-W.C.; funding acquisition, J.-W.C.; The manuscript was written through the contributions of all authors. All authors have read and agreed to the published version of the manuscript.

**Funding:** J.-W.C. acknowledges partial financial support by the National Research Foundation of Korea (NRF) grant funded by the government of Korea (MSIT) (No. 2019R1A2C3002300) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2016R1A6A1A03012845). J.-H.L. acknowledges partial financial support by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1C1C1011876).

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Ratajczak, J.; Miekus, K.; Kucia, M.; Zhang, J.; Reca, R.; Dvorák, P.; Ratajczak, M.Z. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery. *Leukemia* 2006, 20, 847–856. [CrossRef] [PubMed]

2. Vlassov, A.V.; Magdaleno, S.; Setterquist, R.; Conrad, R. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochim. Biophys. Acta Gen. Subj.* 2012, 1820, 940–948. [CrossRef] [PubMed]

3. Théry, C.; Ostrowski, M.; Segura, E. Membrane vesicles as conveyors of immune responses. *Nat. Rev. Immunol.* 2009, 9, 581–593. [CrossRef] [PubMed]

4. Kang, Y.J.; Cutler, E.G.; Cho, H. Therapeutic nanoplatforms and delivery strategies for neurological disorders. *Nano Converg.* 2018, 5, 35. [CrossRef]

5. Shao, H.; Im, H.; Castro, C.M.; Breakefield, X.; Weissleder, R.; Lee, H. New Technologies for Analysis of Extracellular Vesicles. *Chem. Rev.* 2018, 118, 1917–1950. [CrossRef]

6. Huang, X.; Yuan, T.; Tschannen, M.; Sun, Z.-F.; Jacob, H.J.; Du, M.; Liang, M.; Dittmar, R.L.; Liu, Y.; Liang, M.; et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. *BMC Genom.* 2013, 14, 1–14. [CrossRef]

7. Johnsen, K.B.; Gudbergsson, J.M.; Andresen, T.L.; Simonsen, J.B. What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer. *Biochim. Biophys. Acta Bioenerg.* 2018, 1871, 109–116. [CrossRef]

8. Xu, R.; Rai, A.; Chen, M.; Suwakulsiri, W.; Greening, D.W.; Simpson, R.J. Extracellular vesicles in cancer—Implications for future improvements in cancer care. *Nat. Rev. Clin. Oncol.* 2018, 15, 617–638. [CrossRef]

9. Lund, E.; Guttinger, S.; Calado, A.; Dahlberg, J.E.; Kutay, U. Nuclear Export of MicroRNA Precursors. *Science* 2004, 303, 95–98. [CrossRef]

10. Lai, E.C. Micro RNAs are Complementary to 3′ UTR Sequence Motifs that Mediate Negative Post-Transcriptional Regulation. *Nat. Genet.* 2002, 30, 363. [CrossRef]

11. Xu, H.; Ye, B.-C. Advances in biosensing technologies for analysis of cancer-derived exosomes. *TrAC Trends Anal. Chem.* 2020, 123, 115773. [CrossRef]

12. Ibsen, S.D.; Wright, J.; Lewis, J.M.; Kim, S.; Ko, S.-Y.; Ong, J.; Manouchehri, S.; Vyas, A.; Akers, J.; Chen, C.C.; et al. Rapid Isolation and Detection of Exosomes and Associated Biomarkers from Plasma. *ACS Nano* 2017, 11, 6641–6651. [CrossRef] [PubMed]
13. Greening, D.W.; Xu, R.; Ji, H.; Tauro, B.J.; Simpson, R.J. A Protocol for Exosome Isolation and Characterization: Evaluation of Ultracentrifugation, Density-Gradient Separation, and Immunoaffinity Capture Methods. In *Proteomic Profiling*; Springer: Berlin/Heidelberg, Germany, 2015; pp. 179–209.

14. Melo, S.A.; Luecke, L.B.; Kahler, C.; Fernández, A.F.; Gammon, S.T.; Kaye, J.; le Bleu, V.S.; Mittendorf, E.A.; Weitz, J.; Rahbari, N.; et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. *Nature 2015*, *523*, 177–182. [CrossRef] [PubMed]

15. Taylor, D.D.; Zacharias, W.; Gercel-Taylor, C. Exosome Isolation for Proteomic Analyses and RNA Profiling. In *Serum/Plasma Proteomics*; Springer: Berlin/Heidelberg, Germany, 2011; pp. 235–246.

16. Gangoda, L.; Liem, M.; Ang, C.-S.; Keerthikumar, S.; Adda, C.G.; Parker, B.S.; Mathivanan, S. Proteomic Profiling of Exosomes Secreted by Breast Cancer Cells with Varying Metastatic Potential. *Proteomics 2017*, *17*, 1600370. [CrossRef]

17. Yu, J.; Lin, Y.; Xiong, X.; Li, K.; Yao, Z.; Dong, H.; Jiang, Z.; Yu, D.; Yeung, S.-C.J.; Zhang, H. Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis. *Front. Genet. 2019*, *10*, 202. [CrossRef]

18. Merdalimova, A.; Chernyshev, V.; Nozdriukhin, D.; Rudakovskaya, P.; Gorin, D.A.; Yashchenok, A.M. Identification and Analysis of Exosomes by Surface-Enhanced Raman Spectroscopy. *Appl. Sci. 2019*, *9*, 1135. [CrossRef]

19. Bu, J.; Shim, J.-E.; Lee, T.H.; Cho, Y.-H. Multi-Modal liquid biopsy platform for cancer screening: Screening both cancer-associated rare cells and cancer cell-derived vesicles on the fabric filters for a reliable liquid biopsy analysis. *Nano Converg. 2019*, *6*, 1–8. [CrossRef] [PubMed]

20. Im, H.; Lee, K.; Weissleder, R.; Lee, H.; Castro, C.M. Novel nanosensing technologies for exosome detection and profiling. *Lab Chip 2017*, *17*, 2892–2898. [CrossRef]

21. Shao, B.; Xiao, Z. Recent achievements in exosomal biomarkers detection by nanomaterials-based optical biosensors—A review. *Anal. Chim. Acta 2020*, *1114*, 74–84. [CrossRef]

22. Singh, P. SPR Biosensors: Historical Perspectives and Current Challenges. *Sens. Actuators B Chem. 2016*, *229*, 110–130. [CrossRef]

23. Kim, D.; Choi, E.; Lee, C.; Choi, Y.; Kim, H.; Yu, T.; Piao, Y. Highly sensitive and selective visual detection of Cr (VI) ions based on etching of silver-coated gold nanorods. *Nano Converg. 2019*, *6*, 34–39. [CrossRef] [PubMed]

24. Kim, D.W.; Chun, H.J.; Kim, J.-H.; Yoon, H.; Yoon, H.C. A non-spectroscopic optical biosensor for the detection of pathogenic Salmonella Typhimurium based on a stem-loop DNA probe and retro-reflective signaling. *Nano Converg. 2019*, *6*, 16. [CrossRef] [PubMed]

25. Ma, Y.; Dong, B.; Lee, C. Progress of infrared guided-wave nanophotonic sensors and devices. *Nano Converg. 2020*, *7*, 12–34. [CrossRef] [PubMed]

26. Lee, J.-H.; Kim, B.-C.; Oh, B.-K.; Choi, J.-W. Highly sensitive localized surface plasmon resonance immunosensor for label-free detection of HIV-1. *Nanomedicine 2013*, *9*, 1018–1026. [CrossRef]

27. Gong, C.; Leite, M. Noble Metal Alloys for Plasmonics. *ACS Photonics 2016*, *3*, 507–513. [CrossRef]

28. Haes, A.J.; Zou, S.; Schatz, G.C.; van Duyne, R.P. Nanoscale Optical Biosensor: Short Range Distance Dependence of the Localized Surface Plasmon Resonance of Noble Metal Nanoparticles. *J. Phys. Chem. B 2004*, *108*, 6961–6968. [CrossRef]

29. Sugawa, K.; Tahara, H.; Yamashita, A.; Otsuki, J.; Sagara, T.; Harumoto, T.; Yanagida, S. Refractive Index Susceptibility of the Plasmonic Palladium Nanoparticle: Potential as the Third Plasmonic Sensing Material. *ACS Nano 2015*, *9*, 1895–1904. [CrossRef]

30. Haes, A.J.; Zou, S.; Schatz, G.C.; van Duyne, R.P. A Nanoscale Optical Biosensor: The Long Range Distance Dependence of the Localized Surface Plasmon Resonance of Noble Metal Nanoparticles. *J. Phys. Chem. B 2004*, *108*, 109–116. [CrossRef]

31. Yang, L.; Lee, J.-H.; Rathnam, C.; Hou, Y.; Choi, J.-W.; Lee, K.-B. Dual-Enhanced Raman Scattering-Based Characterization of Stem Cell Differentiation Using Graphene-Plasmonic Hybrid Nanoarray. *Nano Lett. 2019*, *19*, 8138–8148. [CrossRef]

32. Jain, P.K.; Huang, X.; El-Sayed, I.H.; El-Sayed, M.A. Review of Some Interesting Surface Plasmon Resonance-enhanced Properties of Noble Metal Nanoparticles and Their Applications to Biosystems. *Plasmonics 2007*, *2*, 107–118. [CrossRef]

33. Nguyen, H.H.; Park, J.; Kang, S.; Kim, M. Surface Plasmon Resonance: A Versatile Technique for Biosensor Applications. *Sensors 2015*, *15*, 10481–10510. [CrossRef] [PubMed]
34. Brolo, A.G. Plasmonics for future biosensors. Nat. Photonics 2012, 6, 709–713. [CrossRef]
35. Belotelov, V.; Akimov, I.; Pohl, M.; Kalish, A.; Kasture, S.; Vengurlekar, A.; Gopal, A.; Kotov, V.; Yakovlev, D.; Zvezdin, A. Intensity magneto-optical effect in magnetoplasmonic crystals. J. Phys. Conference Ser. 2011, 303, 012038. [CrossRef]
36. Rizal, C.; Belotelov, V. Sensitivity comparison of surface plasmon resonance (SPR) and magneto-optic SPR biosensors. Eur. Phys. J. Plus 2019, 134, 435. [CrossRef]
37. Leung, A.; Shankar, P.; Mutharasan, R. A review of fiber-optic biosensors. Sens. Actuators B Chem. 2007, 125, 688–703. [CrossRef]
38. Jing, J.-Y.; Wang, Q.; Zhao, W.-M.; Wang, B.-T. Long-Range surface plasmon resonance and its sensing applications: A review. Opt. Lasers Eng. 2019, 112, 103–118. [CrossRef]
39. Vlček, J.; Pištora, J.; Lesná, M. Design of Plasmonic-Waveguiding Structures for Sensor Applications. Nanomaterials 2019, 9, 1227. [CrossRef]
40. Shpacovitch, V.; Hergenröder, R. Optical and surface plasmonic approaches to characterize extracellular vesicles. A review. Anal. Chim. Acta 2018, 1005, 1–15. [CrossRef]
41. Qiu, G.; Thakur, A.; Xu, C.; Ng, S.P.; Lee, Y.J.; Wu, C.M.L. Detection of Glioma-Derived Exosomes with the Biotinylated Antibody-Functionalyzed Titanium Nitride Plasmonic Biosensor. Adv. Funct. Mater. 2018, 29, 1806761. [CrossRef]
42. Wang, Q.; Zou, L.; Yang, X.; Liu, X.; Nie, W.; Zheng, Y.; Cheng, Q.; Wang, K. Direct quantification of cancerous exosomes via surface plasmon resonance with dual gold nanoparticle-assisted signal amplification. Biosens. Bioelectron. 2019, 135, 129–136. [CrossRef]
43. Im, H.; Shao, H.; Park, Y.I.; Peterson, V.M.; Castro, C.M.; Weissleder, R.; Lee, H. Label-Free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat. Biotechnol. 2014, 32, 490–495. [CrossRef] [PubMed]
44. Thakur, A.; Qiu, G.; Ng, S.P.; Guan, J.; Yue, J.; Lee, Y.J.; Wu, C.M.L. Direct detection of two different tumor-derived extracellular vesicles by SAM-AuNIs LSPR biosensor. Biosens. Bioelectron. 2017, 94, 400–407. [CrossRef] [PubMed]
45. Sun, J.; Lu, Y.; He, L.; Pang, J.; Yang, F.; Liu, Y. Colorimetric sensor array based on gold nanoparticles: Design principles and recent advances. TrAC Trends Anal. Chem. 2020, 122, 115754. [CrossRef]
46. Aldewachi, H.; Chalati, T.; Woodroffe, M.N.; Bricklebank, N.; Sharrack, B.; Gardiner, P. Gold nanoparticle-based colorimetric biosensors. Nanoscale 2018, 10, 18–33. [CrossRef] [PubMed]
47. Xia, Y.; Chen, T.; Chen, G.; Weng, Y.; Zeng, L.; Liao, Y.; Chen, W.; Lan, J.; Zhang, J.; Chen, J.-H. A nature-inspired colorimetric and fluorescent dual-modal biosensor for exosomes detection. Talanta 2020, 214, 120851. [CrossRef]
48. Cheng, N.; Du, D.; Wang, X.; Liu, N.; Xu, W.; Luo, Y.; Lin, Y. Recent Advances in Biosensors for Detecting Cancer-Derived Exosomes. Trends Biotechnol. 2019, 37, 1236–1254. [CrossRef]
49. Sabela, M.; Bechelany, M.; Janot, J.M.; Balme, S.; Bisetty, K. A Review of Gold and Silver Nanoparticle-Based Colorimetric Sensing Assays. Adv. Eng. Mater. 2017, 19, 1700270. [CrossRef] [PubMed]
50. Chen, Z.; Cheng, S.-B.; Cao, P.; Qiu, Q.-F.; Chen, Y.; Xu, Y.; Xie, M.; Huang, W.-H. Detection of exosomes by ZnO nanowires coated three-dimensional scaffold chip device. Biosens. Bioelectron. 2018, 122, 211–216. [CrossRef] [PubMed]
51. Zhang, P.; Zhou, X.; He, M.; Shang, Y.; Tetlow, A.L.; Godwin, A.K.; Zeng, Y. Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip. Nat. Biomed. Eng. 2019, 3, 438–451. [CrossRef] [PubMed]
55. Xia, Y.; Liu, M.; Wang, L.; Yan, A.; He, W.; Chen, M.; Lan, J.; Xu, J.; Guan, L.; Chen, J. A visible and
colorimetric aptasensor based on DNA-capped single-walled carbon nanotubes for detection of exosomes.
*Biosens. Bioelectron.* 2017, 92, 8–15. [CrossRef] [PubMed]

56. Chen, J.; Xu, Y.; Lu, Y.; Xing, W. Isolation and Visible Detection of Tumor-Derived exosomes from Plasma.
*Anal. Chem.* 2018, 90, 14207–14215. [CrossRef] [PubMed]

57. Jiang, Y.; Shi, M.; Liu, Y.; Wan, S.; Cui, C.; Zhang, L.; Tan, W. Aptamer/AuNP Biosensor for Colorimetric
Profiling of Exosomal Proteins. *Angew. Chem. Int. Ed.* 2017, 56, 11916–11920. [CrossRef]

58. Liu, W.; Li, J.; Wu, Y.; Xing, S.; Lai, Y.; Zhang, G. Target-Induced proximity ligation triggers recombinase
polymerase amplification and transcription-mediated amplification to detect tumor-derived exosomes in
nasopharyngeal carcinoma with high sensitivity. *Biosens. Bioelectron.* 2018, 102, 204–210. [CrossRef]

59. Sposito, A.J.; Kurdekar, A.; Zhao, J.; Hewlett, I. Application of nanotechnology in biosensors for enhancing
pathogen detection. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 2018, 10, e1512. [CrossRef]

60. Beitollahi, H.; Ivari, S.G.; Torkzadeh-Mahani, M. Application of antibody–nanogold–ionic liquid–carbon paste
Based Exosomal miRNA Detection. *ACS Nano* 2019, 13, 8793–8803. [CrossRef]

61. Jin, D.; Yang, F.; Zhang, Y.L.; Liu, L.; Zhou, Y.; Wang, F.; Zhang, G.-J. ExoAPP: Exosome-Oriented, Aptamer
Nanoprobe-Enabled Surface Proteins Profiling and Detection. *Anal. Chem.* 2018, 90, 14402–14411. [CrossRef]

62. Lee, J.-H.; Choi, J.-H.; Chueng, S.-T.D.; Pongkulapa, T.; Yang, L.; Cho, H.-Y.; Choi, J.-W.; Lee, K.-B.
Nondestructive Characterization of Stem Cell Neurogenesis by a Magneto-Plasmonic Nanomaterial-Based
Exosomal miRNA Detection. *ACS Nano* 2019, 13, 8793–8803. [CrossRef]

63. Zhang, Q.; Wang, F.; Zhang, H.; Zhang, Y.; Liu, M.; Liu, Y. Universal Ti3C2 MXenes Based Self-Standard
Ratiometric Fluorescence Resonance Energy Transfer Platform for Highly Sensitive Detection of exosomes.
*Anal. Chem.* 2018, 90, 12737–12744. [CrossRef] [PubMed]

64. He, F.; Wang, J.; Yin, B.-C.; Ye, B.-C. Quantification of Exosome Based on a Copper-Mediated Signal
Amplification Strategy. *Anal. Chem.* 2018, 90, 8072–8079. [CrossRef] [PubMed]

65. Zhu, C.; Du, D.; Lin, Y. Graphene-Like 2D nanomaterial-based biointerfaces for biosensing applications.
*Biosens. Bioelectron.* 2017, 89, 43–55. [CrossRef] [PubMed]

66. Saidur, M.; Aziz, A.A.; Basirun, W. Recent advances in DNA-based electrochemical biosensors for heavy
metal ion detection: A review. *Biosens. Bioelectron.* 2017, 90, 125–139. [CrossRef]

67. Shao, Y.; Wang, J.; Wu, H.; Liu, J.; Aksay, I.A.; Lin, Y. Graphene Based Electrochemical Sensors and Biosensors:
A Review. *Electroanalysis* 2010, 22, 1027–1036. [CrossRef]

68. Wang, J. Carbon-Nanotube Based Electrochemical Biosensors: A Review. *Electroanalysis* 2005, 17, 7–14.
[CrossRef]

69. Huang, K.-J.; Wu, X. Recent advances in transition-metal dichalcogenides based electrochemical biosensors: A review. *Biosens. Bioelectron.* 2017, 97, 305–316. [CrossRef]

70. Hu, T.; Zhang, L.; Wen, W.; Zhang, X.; Wang, S. Enzyme catalytic amplification of miRNA-155 detection with
graphene quantum dot-based electrochemical biosensor. *Biosens. Bioelectron.* 2016, 77, 451–456. [CrossRef]

71. Beitollahi, H.; Ivari, S.G.; Torkzadeh-Mahani, M. Application of antibody–nanogold–ionic liquid–carbon paste
electrode for sensitive electrochemical immunoassay of thyroid-stimulating hormone. *Biosens. Bioelectron.*
2018, 110, 97–102. [CrossRef]

72. Figueroa-Miranda, G.; Feng, L.; Shiu, S.C.-C.; Dirkzwager, R.M.; Cheung, Y.-W.; Tanner, J.A.; Schöning, M.J.;
Offenhäusser, A.; Mayer, D. Aptamer-Based electrochemical biosensor for highly sensitive and selective
malaria detection with adjustable dynamic response range and reusability. *Sens. Actuators B Chem.* 2018, 255,
235–243. [CrossRef]

73. Huang, Y.L.; Mo, S.; Gao, Z.F.; Chen, J.R.; Lei, J.L.; Luo, H.Q.; Li, N.B. Amperometric biosensor for
microRNA based on the use of tetrahedral DNA nanostructure probes and guanine nanowire amplification.
*Microchim. Acta* 2017, 481, 190–2604. [CrossRef]

74. Ding, J.; Qin, W. Recent advances in potentiometric biosensors. *TrAC Trends Anal. Chem.* 2020, 124, 115803.
[CrossRef]

75. Doldán, X.; Fagúndez, P.; Cayota, A.; Laiz, J.; Tosar, J.P. Electrochemical Sandwich Immunosensor for
Determination of Exosomes Based on Surface Marker-Mediated Signal Amplification. *Anal. Chem.* 2016, 88,
10466–10473. [CrossRef] [PubMed]
76. Cao, Y.; Li, L.; Han, B.; Wang, Y.; Dai, Y.; Zhao, J. A catalytic molecule-machine-driven biosensing method for amplified electrochemical detection of exosomes. *Biosens. Bioelectron.* 2019, 141, 111397. [CrossRef] [PubMed]

77. Moura, S.L.; Martin, C.G.; Marti, M.; Pividori, M. Electrochemical immunosensing of nanovesicles as biomarkers for breast cancer. *Biosens. Bioelectron.* 2019, 150, 111882. [CrossRef] [PubMed]

78. An, Y.; Li, R.; Zhang, F.; He, P. Magneto-Mediated Electrochemical Sensor for Simultaneous Analysis of Breast Cancer Exosomal Proteins. *Anal. Chem.* 2020, 92, 5404–5410. [CrossRef]

79. Wang, S.; Zhang, L.; Wan, S.; Cansiz, S.; Cui, C.; Liu, Y.; Cai, R.; Hong, C.-Y.; Teng, L.-T.; Shi, M.; et al. Aptsensor with Expanded Nucleotide Using DNA Nanotetrahedra for Electrochemical Detection of Cancerous Exosomes. *ACS Nano* 2017, 11, 3943–3949. [CrossRef]

80. Huang, R.; He, L.; Xia, Y.; Xu, H.; Liu, C.; Xie, H.; Wang, S.; Peng, L.; Liu, Y.; Liu, Y.; et al. A Sensitive Aptsensor Based on a Hemin/G-Quadruplex-Assisted Signal Amplification Strategy for Electrochemical Detection of Gastric Cancer Exosomes. *Small* 2019, 15, e1900735. [CrossRef]

81. Ding, S.-Y.; You, E.-M.; Tian, Z.-Q.; Moskovits, M. Electromagnetic theories of surface-enhanced Raman spectroscopy. *Chem. Soc. Rev.* 2017, 46, 4042–4076. [CrossRef]

82. Dong, H.; Chen, H.; Jiang, J.; Zhang, H.; Cai, C.; Shen, Q. Highly Sensitive Electrochemical Detection of Tumor Exosomes Based on Aptamer Recognition-Induced Multi-DNA Release and Cyclic Enzymatic Amplification. *Anal. Chem.* 2018, 90, 4507–4513. [CrossRef]

83. An, Y.; Jin, T.; Zhu, Y.; Zhang, F.; He, P. An ultrasensitive electrochemical aptasensor for the determination of tumor biomarkers based on click chemistry. *Biosens. Bioelectron.* 2019, 142, 111503. [CrossRef] [PubMed]

84. Zhao, L.; Sun, R.; He, P.; Zhang, X. Ultrasensitive Detection of Exosomes by Target-Triggered Three-Dimensional DNA Walking Machine and Exonuclease III-Assisted Electrochemical Ratiometric Biosensing. *Anal. Chem.* 2019, 91, 14773–14779. [CrossRef] [PubMed]

85. Yin, X.; Hou, T.; Huang, B.; Yang, L.; Li, F. Aptamer recognition-trigged label-free homogeneous electrochemical strategy for an ultrasensitive cancer-derived exosome assay. *Chem. Commun.* 2019, 55, 13705–13708. [CrossRef] [PubMed]

86. Third, A.; Wilson, C. Exosomal miRNAs as cancer biomarkers and therapeutic targets. *J. Extracell. Vesicles* 2016, 5, 281. [CrossRef]

87. Salehi, M.; Sharifi, M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. *J. Cell. Physiol.* 2018, 233, 6370–6380. [CrossRef]

88. Jin, X.; Chen, Y.; Chen, H.; Fei, S.; Chen, D.; Cai, X.; Liu, L.; Lin, B.; Su, H.; Zhao, L.; et al. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing. *Clin. Cancer Res.* 2017, 23, 5311–5319. [CrossRef]

89. Boriachek, K.; Umer, M.; Islam, N.; Gopalan, V.; Lam, A.K.-Y.; Nguyen, N.-T.; Shiddiky, M.J.A. An amplification-free electrochemical detection of exosomal miRNA-21 in serum samples. *Analyst* 2018, 143, 1662–1669. [CrossRef]

90. Luo, L.; Wang, L.; Zeng, L.; Wang, Y.; Weng, Y.; Liao, Y.; Chen, T.; Xia, Y.; Zhang, J.; Chen, J.-H. A ratiometric electrochemical DNA biosensor for detection of exosomal MicroRNA. *Talanta* 2019, 207, 120298. [CrossRef]

91. Guo, Q.; Yu, Y.; Zhang, H.; Cai, C.; Shen, Q. Electrochemical Sensing of Exosomal MicroRNA Based on Hybridization Chain Reaction Signal Amplification with Reduced False-Positive Signals. *Anal. Chem.* 2020, 92, 5302–5310. [CrossRef]

92. Cheng, W.; Ma, J.; Cao, P.; Zhang, Y.; Xu, C.; Yi, Y.; Li, J. Enzyme-Free electrochemical biosensor based on double signal amplification strategy for the ultra-sensitive detection of exosomal microRNAs in biological samples. *Talanta* 2020, 121242. [CrossRef]

93. Ding, S.-Y.; Yi, J.; Li, J.-F.; Ren, B.; Wu, D.-Y.; Selvam, R.P.P.; Tian, Z.-Q. Nanostructure-Based plasmon-enhanced Raman spectroscopy for surface analysis of materials. *Nat. Rev. Mater.* 2016, 1, 16021. [CrossRef]

94. Mosier-Boss, P. Review of SERS Substrates for Chemical Sensing. *Nanoscale Mater.* 2017, 7, 142. [CrossRef] [PubMed]

95. El-Said, W.A.; Yoon, J.; Choi, J.-W. Nanostructured surfaces for analysis of anticancer drug and cell diagnosis based on electrochemical and SERS tools. *Nano Converg.* 2018, 5, 1–19. [CrossRef] [PubMed]

96. Fan, M.; Andrade, G.F.; Brolo, A.G. A review on recent advances in the applications of surface-enhanced Raman scattering in analytical chemistry. *Anal. Chim. Acta* 2019, 1087, 1–29. [CrossRef]
97. Tian, Y.-F.; Ning, C.-F.; He, F.; Yin, B.-C.; Ye, B.-C. Highly sensitive detection of exosomes by SERS using gold nanostar@Raman reporter@nanoshell structures modified with a bivalent cholesterol-labeled DNA anchor. *Analyst* 2018, 143, 4915–4922. [CrossRef]

98. Kwizera, E.A.; O’Connor, R.; Vinduska, V.; Williams, M.; Butch, E.R.; Snyder, S.E.; Chen, X.; Huang, X. Molecular Detection and Analysis of Exosomes Using Surface-Enhanced Raman Scattering Gold Nanorods and a Miniaturized Device. *THERANOSTICS* 2018, 8, 2722. [CrossRef]

99. Zhang, W.; Jiang, L.; Diefenbach, R.J.; Campbell, D.H.; Walsh, B.J.; Packer, N.H.; Wang, Y. Enabling Sensitive Phenotypic Profiling of Cancer-Derived Small Extracellular Vesicles Using Surface-Enhanced Raman Spectroscopy Nanotags. *ACS Sens.* 2020, 5, 764–771. [CrossRef]

100. Pang, Y.; Shi, J.; Yang, X.; Wang, C.; Sun, Z.; Xiao, R. Personalized detection of circling exosomal PD-L1 based on Fe3O4@TiO2 isolation and SERS immunoassay. *Biosens. Bioelectron.* 2019, 118, 111800. [CrossRef]

101. Wang, Z.; Zong, S.; Wang, Y.; Li, L.; Li, L.; Su, Z.; Chang, B.; Cui, Y. Screening and multiple detection of cancer exosomes using an SERS-based method. *Nanoscale* 2018, 10, 9053–9062. [CrossRef]

102. Zhang, X.; Liu, C.; Pei, Y.; Song, W.; Zhang, S. Preparation of a Novel Raman Probe and Its Application in the Detection of Circulating Tumor Cells and Exosomes. *ACS Appl. Mater. Interfaces* 2019, 11, 28671–28680. [CrossRef]

103. Ma, D.; Huang, C.; Zheng, J.; Tang, J.; Li, J.; Yang, J.; Tan, W. Quantitative detection of exosomal microRNA extracted from human blood based on surface-enhanced Raman scattering. *Biosens. Bioelectron.* 2018, 101, 167–173. [CrossRef] [PubMed]

104. Zhu, K.; Wang, Z.; Zong, S.; Liu, Y.; Yang, K.; Li, N.; Wang, Z.; Li, L.; Tang, H.; Cui, Y. Hydrophobic Plasmonic Nanoacorn Array for a Label-Free and Uniform SERS-Based Biomolecular Assay. *ACS Appl. Mater. Interfaces* 2020. [CrossRef] [PubMed]

105. Ning, C.-F.; Wang, L.; Tian, Y.-F.; Yin, B.-C.; Ye, B.-C. Multiple and sensitive SERS detection of cancer-related exosomes based on gold-silver bimetallic nanotrepangs. *Analyst* 2020, 145, 2795–2804. [CrossRef] [PubMed]

106. Lee, J.U.; Kim, W.H.; Lee, H.S.; Park, K.H.; Sim, S.J. Quantitative and Specific Detection of Exosomal miRNAs for Accurate Diagnosis of Breast Cancer Using a Surface-Enhanced Raman Scattering Sensor Based on Plasmonic Head-Flocked Gold Nanopillars. *Small* 2019, 15, e1804968. [CrossRef] [PubMed]

107. Tsang, D.K.H.; Lieberthal, T.; Watts, C.; Dunlop, I.E.; Ramadan, S.; Hernández, A.E.D.R.; Klein, N. Chemically Functionalised Graphene FET Biosensor for the Label-Free Sensing of Exosomes. *Sci. Rep.* 2019, 9, 13946. [CrossRef]

108. Yu, Y.; Li, Y.-T.; Jin, D.; Yang, F.; Wu, D.; Xiao, M.-M.; Zhang, H.; Zhang, Z.; Zhang, G.-J. Electrical and Label-Free Quantification of Exosomes with a Reduced Graphene Oxide Field Effect Transistor Biosensor. *Anal. Chem.* 2019, 91, 10679–10686. [CrossRef]

109. Etayash, H.; McGee, A.R.; Kaur, K.; Thundat, T. Nanomechanical sandwich assay for multiple cancer biomarkers in breast cancer cell-derived exosomes. *Nanoscale* 2016, 8, 15137–15141. [CrossRef]

110. Chang, Y.-J.; Yang, W.-T.; Wu, J.-C. Isolation and detection of exosomes via AAO membrane and QCM measurement. *Microelectron. Eng.* 2019, 216, 111094. [CrossRef]

111. Suthar, J.; Parsons, E.S.; Hoogenboom, B.W.; Williams, G.R.; Guldin, S. Acoustic Immunosensing of Exosomes Using a Quartz Crystal Microbalance with Dissipation Monitoring. *Anal. Chem.* 2020, 92, 4082–4093. [CrossRef]

112. Zhu, F.; Li, D.; Ding, Q.; Lei, C.; Ren, L.; Ding, X.; Sun, X. 2D magnetic MoS2–Fe3O4 hybrid nanostructures for ultrasensitive exosome detection in GMR sensor. *Biosens. Bioelectron.* 2020, 147, 111787. [CrossRef]

113. Ertsgaard, C.T.; Wittenberg, N.J.; Klemme, D.J.; Barik, A.; Shih, W.-C.; Oh, S.-H. Integrated Nanogap Platform for Sub-Volt Dielectrophoretic Trapping and Real-Time Raman Imaging of Biological Nanoparticles. *Nano Lett.* 2018, 18, 5946–5953. [CrossRef] [PubMed]

114. Yan, Z.; Dutta, S.; Liu, Z.; Yu, X.; Mesgarzadeh, N.; Ji, F.; Bitan, G.; Xie, Y.-H. A Label-Free Platform for Identification of Exosomes from Different Sources. *ACS Sens.* 2019, 4, 488–497. [CrossRef] [PubMed]

115. Rabinowits, G.; Gercel-Taylor, C.; Day, J.M.; Taylor, U.D.; Kloecker, G.H. Exosomal MicroRNA: A Diagnostic Marker for Lung Cancer. *Clin. Lung Cancer* 2009, 10, 42–46. [CrossRef] [PubMed]
116. Ogata-Kawata, H.; Izumiya, M.; Kurioka, D.; Honma, Y.; Yamada, Y.; Furuta, K.; Gunji, T.; Ohta, H.; Okamoto, H.; Sonoda, H.; et al. Circulating Exosomal microRNAs as Biomarkers of Colon Cancer. *PLoS ONE* **2014**, *9*, e92921. [CrossRef]

117. Cho, S.; Yang, H.C.; Rhee, W.J. Simultaneous multiplexed detection of exosomal microRNAs and surface proteins for prostate cancer diagnosis. *Biosens. Bioelectron.* **2019**, *146*, 111749. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).